Study progress of T-lymphoblastic lymphoma in children
10.3760/cma.j.issn.2095-428X.2019.01.017
- VernacularTitle:儿童T淋巴母细胞淋巴瘤研究进展
- Author:
Yanqin CHENG
1
;
Xiaowen ZHAI
;
Lian CHEN
Author Information
1. 复旦大学附属儿科医院血液科
- Keywords:
Lymphoblastic lymphoma;
Immunophennotype;
Gene mutation;
Therapy;
Next-generaion sequencing;
Minimal residual disease;
Stem cell transplantation
- From:
Chinese Journal of Applied Clinical Pediatrics
2019;34(1):68-72
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoblastic lymphoma (LBL) is a rare aggressive neoplasm of T-/B-precursors resembling acute lymphoblastic leukemia,which develops very fast with high morbidity.T-lymphoblastic lymphoma (T-LBL),accounting for 85％-90％ of LBL,develops more frequently in children and young adults and is typically characterized by a grossly enlarged mediastinum,whose diagnostic hallmark is the expression of a T-precursor cell immunophenotype.Recently many new diagnostic technologies,such as polymerase chain reaction,flow cytometry,fluorescence in situ hybridization and so on,have been used for the dignosis of LBL,which lay the foundation of the precision therapy for LBL.The adoption of pediatric-derived,intensive lymphoblastic leukemia-like protocols leads to significantly improved results,with event free survival about 75％-90％ in children.New clinical trials will introduce and confirm the value of new drugs and targeting agents,which may have more good effects.New minimal residual disease assessment methods(eg,next generation sequencing,NGS) make it possible to detect MRD in different subtype of childhood lymphomas.Now,the new advances in diagnosis and treatment of T-LBL were reviewed.
